Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.06 CNY
−70.96 M CNY
1.28 B CNY
164.20 M
About NANJING VAZYME BIOTECH
Sector
Industry
CEO
Lin Cao
Website
Headquarters
Nanjing
Founded
2012
ISIN
CNE100004ZK3
FIGI
BBG00YPHTNW3
Nanjing Vazyme Biotech Co., Ltd. engages in the research and development, and production of antibody drugs. Its products include Biological reagents and In vitro diagnostic products. The biological reagents products consist of polymerase chain reaction series, molecular cloning series, reverse record series, gene sequencing series, bio-assay series, and cell and protein series. The In vitro diagnostic products encompass point-of-care testing diagnostic reagents and instrument. The company was founded on March 16, 2012 and is headquartered in Nanjing, China.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 688105 is 23.64 CNY — it has decreased by −1.52% in the past 24 hours. Watch NANJING VAZYME BIOTECH stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SSE exchange NANJING VAZYME BIOTECH stocks are traded under the ticker 688105.
688105 stock has fallen by −3.88% compared to the previous week, the month change is a −6.99% fall, over the last year NANJING VAZYME BIOTECH has showed a −26.79% decrease.
We've gathered analysts' opinions on NANJING VAZYME BIOTECH future price: according to them, 688105 price has a max estimate of 27.00 CNY and a min estimate of 27.00 CNY. Watch 688105 chart and read a more detailed NANJING VAZYME BIOTECH stock forecast: see what analysts think of NANJING VAZYME BIOTECH and suggest that you do with its stocks.
688105 reached its all-time high on Dec 22, 2021 with the price of 130.50 CNY, and its all-time low was 16.85 CNY and was reached on Sep 23, 2024. View more price dynamics on 688105 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
688105 stock is 2.54% volatile and has beta coefficient of 1.79. Track NANJING VAZYME BIOTECH stock price on the chart and check out the list of the most volatile stocks — is NANJING VAZYME BIOTECH there?
Today NANJING VAZYME BIOTECH has the market capitalization of 9.39 B, it has decreased by −5.62% over the last week.
Yes, you can track NANJING VAZYME BIOTECH financials in yearly and quarterly reports right on TradingView.
NANJING VAZYME BIOTECH is going to release the next earnings report on Apr 18, 2025. Keep track of upcoming events with our Earnings Calendar.
688105 net income for the last quarter is 2.00 M CNY, while the quarter before that showed 10.94 M CNY of net income which accounts for −81.75% change. Track more NANJING VAZYME BIOTECH financial stats to get the full picture.
As of Dec 23, 2024, the company has 2.70 K employees. See our rating of the largest employees — is NANJING VAZYME BIOTECH on this list?
Like other stocks, 688105 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NANJING VAZYME BIOTECH stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NANJING VAZYME BIOTECH technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NANJING VAZYME BIOTECH stock shows the sell signal. See more of NANJING VAZYME BIOTECH technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.